Human recombinant soluble tumor necrosis factor (TNF) α receptors (etanercept) and monoclonal antibodies to TNF-α (infliximab and adalimumab) have been used successfully to treat a wide range of inflammatory conditions, including psoriasis. We report 1 case of plaque-type psoriasis and 2 cases of pustular psoriasis that developed in patients with no history of psoriasis who were being treated with TNF-α antagonists.
A 65-year-old woman with a history of rheumatoid arthritis that had been treated for 4 years with infliximab and was well controlled with maintenance therapy (3 mg/kg every 8 weeks) was seen with a 7-month history of spreading erythematous plaques suggestive of psoriasis or a drug eruption (Figure 1). These plaques began on her legs and then progressed to involve her trunk and extremities. She had no personal or family history of psoriasis and denied any preceding upper respiratory infection.
Ubriani R, Van Voorhees AS. Onset of Psoriasis During Treatment With TNF-α Antagonists: A Report of 3 Cases. Arch Dermatol. 2007;143(2):264–276. doi:10.1001/archderm.143.2.270